Related Experiment Videos
Effect of levamisole on experimental paracoccidioidomycosis in the Syrian hamster: immunologic and histopathologic
Abstract:
The effect of levamisole (LMS) was studied in hamsters inoculated with live yeast phase culture of Paracoccidioides brasiliensis by intratesticular route. One group started LMS therapy at an early stage of infection (LMS3 group), when the animals were immunocompetent, and another group was treated in a later stage, when the immune response was already depressed (LMS12 group). As control, one group was not treated. The alterations induced by levamisole were studied by immunologic and histopathologic parameters. Compared to controls, the LMS3 group presented normal levels of cellular immune response and inflammatory reaction characterized by compact epithelioid granuloma during a longer period of time. In addition, this group showed a lower incidence of amyloidosis and lower fungi proliferation in the lesions. In the LMS12 group a transient enhancement was noteworthy of cellular immune response with maintenance of the compact pattern of the epithelioid granuloma as in the LMS3 group; however, the number of fungi and incidence of amyloidosis were similar to controls. The differences between both treated groups may be accounted for by some factors such as host immune competence, timing and total dose of LMS administered. Levamisole may be of value as additional therapy in paracoccidioidomycosis.
Insights
Early levamisole (LMS) treatment in hamsters with Paracoccidioides brasiliensis infection improved immune response and reduced fungal proliferation. Later treatment showed transient benefits, suggesting timing is crucial for LMS efficacy in paracoccidioidomycosis.
Area of Science:
- Immunology
- Mycology
- Veterinary Medicine
Background:
- Paracoccidioidomycosis is a systemic fungal infection caused by Paracoccidioides brasiliensis.
- The disease affects immunocompetent and immunocompromised individuals, with varying clinical presentations.
- Current treatment options for paracoccidioidomycosis can be limited, necessitating exploration of adjunctive therapies.
Purpose of the Study:
- To evaluate the immunomodulatory effects of levamisole (LMS) in a hamster model of Paracoccidioides brasiliensis infection.
- To compare the efficacy of early versus late-stage LMS administration on the host immune response and disease progression.
- To assess the impact of LMS on fungal burden, granuloma formation, and amyloidosis.
Main Methods:
- Hamsters were inoculated intratesticularly with live yeast-phase Paracoccidioides brasiliensis.
- Levamisole (LMS) treatment was administered either early (LMS3 group) or late (LMS12 group) in the infection course.
- Control groups received no treatment.
- Immunologic and histopathologic parameters were assessed to evaluate treatment effects.
Main Results:
- The early LMS treatment group (LMS3) maintained normal cellular immune response and prolonged epithelioid granuloma formation.
- LMS3 group exhibited reduced amyloidosis incidence and lower fungal proliferation compared to controls.
- The late LMS treatment group (LMS12) showed a transient increase in cellular immune response but similar fungal burden and amyloidosis to controls.
Conclusions:
- Early administration of levamisole (LMS) enhances host immune competence and controls Paracoccidioides brasiliensis proliferation in a hamster model.
- The timing of LMS therapy is critical, with early intervention yielding superior outcomes.
- Levamisole may serve as a valuable adjunctive therapy for paracoccidioidomycosis, particularly when initiated during immunocompetence.